Published on in Vol 8, No 10 (2020): October

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/22108, first published .
Evaluating the Utility of Smartphone-Based Sensor Assessments in Persons With Multiple Sclerosis in the Real-World Using an App (elevateMS): Observational, Prospective Pilot Digital Health Study

Evaluating the Utility of Smartphone-Based Sensor Assessments in Persons With Multiple Sclerosis in the Real-World Using an App (elevateMS): Observational, Prospective Pilot Digital Health Study

Evaluating the Utility of Smartphone-Based Sensor Assessments in Persons With Multiple Sclerosis in the Real-World Using an App (elevateMS): Observational, Prospective Pilot Digital Health Study

Journals

  1. Hsieh K, Fanning J, Frechette M, Sosnoff J. Usability of a Fall Risk Mobile Health Application for People with Multiple Sclerosis: A Mixed Methods Study (Preprint). JMIR Human Factors 2020 View
  2. Inojosa H, Akgün K, Haacke K, Ziemssen T. MSProDiscuss – Entwicklung eines digitalen Tools zur standardisierten Patientenanamnese, um Progredienz bei Multipler Sklerose zu identifizieren. Fortschritte der Neurologie · Psychiatrie 2021;89(07/08):374 View
  3. Palotai M, Wallack M, Kujbus G, Dalnoki A, Guttmann C. Usability of a Mobile App for Real-Time Assessment of Fatigue and Related Symptoms in Patients With Multiple Sclerosis: Observational Study. JMIR mHealth and uHealth 2021;9(4):e19564 View
  4. Abou L, Wong E, Peters J, Dossou M, Sosnoff J, Rice L. Smartphone applications to assess gait and postural control in people with multiple sclerosis: A systematic review. Multiple Sclerosis and Related Disorders 2021;51:102943 View
  5. Mokhberdezfuli M, Ayatollahi H, Naser Moghadasi A, Taiar R. A Smartphone-based Application for Self-Management in Multiple Sclerosis. Journal of Healthcare Engineering 2021;2021:1 View
  6. Freeman L, Kee A, Tian M, Mehta R. Retrospective Claims Analysis of Treatment Patterns, Relapse, Utilization, and Cost Among Patients with Multiple Sclerosis Initiating Second-Line Disease-Modifying Therapy. Drugs - Real World Outcomes 2021 View